AI assistant
Circio Holding ASA — AGM Information 2026
May 8, 2026
3769_rns_2026-05-08_351121d7-0c35-488c-9b30-64307b9b4eb7.html
AGM Information
Open in viewerOpens in your device viewer
Circio Holding ASA: Minutes from the annual general meeting 2026
Circio Holding ASA: Minutes from the annual general meeting 2026
Oslo, 8 May 2026: Circio Holding ASA (the "Company") held its annual general
meeting today. The meeting was held as a physical meeting at the premises of
Advokatfirmaet Thommessen AS, Ruseløkkveien 38, 0251 Oslo, Norway.
All resolutions were made in accordance with the proposals from the board of
directors and the nomination committee, including, but not limited to,
approval of the 2025 annual accounts, election of KPMG as the Company's new
auditor and election of members to the board of directors.
The minutes from the annual general meeting are attached hereto and will also
be made available on the Company's website
circio.com/investors/general-meetings
(https://www.circio.com/en/section/investors/general-meetings/).
This information is subject to disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: [email protected]
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.